- Policy
- Limited indications of JAKI for high-risk groups
- by Lee, Hye-Kyung Jun 16, 2022 05:58am
- It was confirmed that the opinions of the Central Pharmaceutical Affairs Council members were also mixed over the limited use of Janus kinase Inhibitors, which is used as a treatment for inflammatory diseases. The MFDS announced on the 15th that high-risk patients aged 65 or older, high-risk cardiovascular groups, and malignant tumors will be
- Policy
- Listing period for new drugs to be reduced up to 60 days
- by Kim, Jung-Ju Jun 16, 2022 05:57am
- The government will reduce the new drug reimbursement listing procedures by up to 60 days to reinforce accessibility to new drugs. Also, the government plans to expand pharmacoeconomic evaluation (PE) exemptions, a mechanism that plays a key role in the deliberations made on the reimbursement adequacy of new drugs. This is a specified pla
- Policy
- Phase 2 of Shinpoong's Pyramax will be conducted again
- by Lee, Hye-Kyung Jun 16, 2022 05:57am
- Shinpoong will conduct phase 2 clinical trials of Pyramax again to prove its safety and effectiveness as a treatment for COVID-19. On the 13th, the MFDS approved a clinical trial to explore the safety and effectiveness of Pyramax in patients with mild or moderate COVID-19. Exploratory clinical trials are clinical trials conducted for the p
- Company
- GC Pharma leads 300 billion flu vaccine market
- by Nho, Byung Chul Jun 15, 2022 07:48pm
- SK Chemicals and GC Pharma are competing in the private 4-valent influenza (flu) vaccine market with an external banding of 200 billion won, the survey showed. SK Chemical's SKY Cellflu Quardrient and GC Flu Quardrient ranked first and second in the private distribution flu vaccine for the past three years (2018, 2019, 2020), with performances o
- Policy
- HIRA to review metformin+SGLT2+DPP4 reimb at last
- by Lee, Tak-Sun Jun 15, 2022 05:51am
- The Health Insurance Review and Assessment Service entered the final steps of its reimbursement review for a 3-drug combination therapy that contains metformin, an SLGT-2 inhibitor, and a DPP-4 inhibitor. Reimbursement of the combined use of SGLT-2 and DPP-4 class oral antidiabetic drugs had been continuously raised as an issue by academ
- Policy
- Policies at a standstill due to absence of MFDS minister
- by Lee, Jeong-Hwan Jun 15, 2022 05:50am
- With the ruling and opposition parties having difficulty coming to an agreement on the composition of the NA leadership, the prolonged policy gap in national disease control and prevention and the pharma-bio industry is intensifying due to the absence of the Minister of Health and Welfare. President Suk-Yeol Yoon’s administration had set
- Company
- Samsung Bioepis Announces Phase 3 Results of Soliris Similar
- by Kim, Jin-Gu Jun 15, 2022 05:50am
- Samsung Bioepis announced on the 13th that it has unveiled the results of phase 3 clinical trials of Soliris (Eculizumab) biosimilar SB12 through the EHA annual academic conference held in Austria from the 9th to the 12th. SB12 is the seventh biosimilar developed by Samsung Bioepis. It is the first blood disease treatment. The original Sol
- Policy
- Lorviqua is about to be reimbursed
- by Lee, Tak-Sun Jun 15, 2022 05:50am
- It is known that Lorviqua, a third-generation ALK-inhibiting non-small cell lung cancer treatment, is on the verge of insurance benefits through drug price negotiations. As a result, new treatment options are expected to be created for patients who have not seen any effect even if they use first and second-generation treatments. The drug w
- Company
- Sales of topical minoxidil rise with interest in hair loss
- by Jun 14, 2022 06:04am
- The market for minoxidil topical solutions that are applied directly to the scalp continued on its strong growth, with marked growth shown by the foam-type Rogaine Foam among the three major products in the market. According to the market research institution IQVIA on the 14th, the minoxidil topical solution market had raised &8361;4.6 b
- Company
- Lilly Korea has entered into negotiations on Emgality
- by Eo, Yun-Ho Jun 14, 2022 06:04am
- CGRP target migraine drug Emgality is in the final stage for insurance benefit registration. According to related industries, Emgality, a target migraine treatment for CGRP (Calcitoninogen-related peptide) by Lilly Korea, recently began negotiations with the NHIS on drug prices. Considering the deadline for negotiations, a conclusion is ex
